Evidence map›Paper›PMID 25755500›Full record

ArticleJournal of clinical and experimental hepatology2013

Long-term Branched Chain Amino Acid Supplementation Ameliorates Diethylnitrosamine-induced Liver Glutathione S-transferase-p Positivity in Zucker Fatty Rats.

Sonoko Ishizaki, Megumi Nishiyama, Asami Hagiwara

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical and experimental hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sonoko IshizakiExploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Co., Ltd., Kawasaki, Japan.
Megumi NishiyamaExploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Co., Ltd., Kawasaki, Japan.
Asami HagiwaraExploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Co., Ltd., Kawasaki, Japan.
Ajinomoto (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObesity increases the risk of fatty liver disease and liver cancer. There are several models of obesity-associated hepatocellular carcinoma, but tumor development in these models is slow. MATERIALS AND

methodsWe investigated Zucker fatty rats, a model of obesity and insulin resistance, to discover if diethylnitrosamine (DEN), a potent liver carcinogen, might enhance liver carcinogenesis. We also investigated the effect of branched chain amino acids (BCAA) against the development of liver cancer.

resultsIncidence and number of hepatocellular carcinomas and adenomas were significantly greater in DEN-treated Zucker fatty rats than in DEN-treated lean rats. All treated Zucker fatty rats developed hepatocellular carcinoma within 16 weeks. Long-term BCAA supplementation significantly reduced expression of CyclinD1, PCNA, thymidine kinase, Bcl-2, and GST-p and increased expression of p21 in the liver. Furthermore, BCAA treatment significantly reduced the area of GST-p positive foci.

conclusionLong-term BCAA treatment may induces cell cycle arrest and apoptotic induction, thus suppressing pre-neoplastic lesions.

Indexed as

BCAABCAA, branched chain amino acidsDEN, diethylnitrosamineDTT, dithiothreitolFLS, fatty liver shionogiGST-p, glutathione S-transferase P-formHBV, hepatitis B virusHCC, hepatocellular carcinomaHCV, hepatitis C virushepatocellular carcinomaobesityPCNA, proliferation cell nuclear antigenTK, thymidine kinase

Identifiers

PMID25755500
PMCPMC3940393
OpenAlexW2061181103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.